Copenhagen University Hospital, Mental Health Center Copenhagen, Hellerup, Denmark.
The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Copenhagen and Aarhus, Denmark.
JAMA Psychiatry. 2018 Jul 1;75(7):733-739. doi: 10.1001/jamapsychiatry.2018.0568.
Understanding the role of substance use disorders in conversion from schizotypal disorder to schizophrenia may provide physicians and psychiatrists with important tools for prevention or early detection of schizophrenia.
To investigate whether substance use disorders, in particular cannabis use disorder, are associated with conversion to schizophrenia in individuals with schizotypal disorder.
DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study included a population-based sample of all individuals born in Denmark from January 1, 1981, through August 10, 2014, with an incident diagnosis of schizotypal disorder and without a previous diagnosis of schizophrenia. Follow-up was completed on August 10, 2014, and data were analyzed from March 10, 2017, through February 15, 2018.
Information on substance use disorders combined from 5 different registers.
Cox proportional hazards regression using time-varying information on substance use disorders and receipt of antipsychotics and adjusted for parental history of mental disorders, sex, birth year, and calendar year were used to estimate hazard ratios (HRs) and 95% CIs for conversion to schizophrenia.
A total of 2539 participants with incident schizotypal disorder were identified (1448 men [57.0%] and 1091 women [43.0%]; mean [SD] age, 20.9 [4.4] years). After 2 years, 16.3% (95% CI, 14.8%-17.8%) experienced conversion to schizophrenia. After 20 years, the conversion rate was 33.1% (95% CI, 29.3%-37.3%) overall and 58.2% (95% CI, 44.8%-72.2%) among those with cannabis use disorders. In fully adjusted models, any substance use disorder was associated with conversion to schizophrenia (HR, 1.34; 95% CI, 1.11-1.63). When data were stratified by substance, cannabis use disorders (HR, 1.30; 95% CI, 1.01-1.68), amphetamine use disorders (HR, 1.90; 95% CI, 1.14-3.17), and opioid use disorders (HR, 2.74; 95% CI, 1.38-5.45) were associated with conversion to schizophrenia. These associations were not explained by concurrent use of antipsychotics, functional level before incident schizotypal disorder, or parental history of mental disorders.
Substance use disorders, in particular cannabis, amphetamines, and opioids, may be associated with conversion from schizotypal disorder to schizophrenia. However, conversion rates are high even in those without substance use disorders, indicating a need for universal and substance-targeted prevention in individuals with schizotypal disorder.
了解物质使用障碍在从精神分裂症谱系障碍到精神分裂症的转化中的作用,可能为医生和精神科医生提供预防或早期发现精神分裂症的重要工具。
研究物质使用障碍,特别是大麻使用障碍,是否与精神分裂症谱系障碍患者向精神分裂症的转化有关。
设计、地点和参与者:这是一项基于人群的队列研究,纳入了 1981 年 1 月 1 日至 2014 年 8 月 10 日期间在丹麦出生的所有个体,这些个体患有精神分裂症谱系障碍且无精神分裂症既往史。随访于 2014 年 8 月 10 日完成,数据分析于 2017 年 3 月 10 日至 2018 年 2 月 15 日进行。
从 5 个不同的登记处综合了物质使用障碍的信息。
使用时间变化的物质使用障碍信息和抗精神病药物使用信息,以及调整了父母精神疾病史、性别、出生年份和日历年份,使用 Cox 比例风险回归来估计转换为精神分裂症的风险比 (HR) 和 95%置信区间。
共确定了 2539 名患有精神分裂症谱系障碍的参与者(1448 名男性[57.0%]和 1091 名女性[43.0%];平均[标准差]年龄为 20.9[4.4]岁)。2 年后,16.3%(95%置信区间,14.8%-17.8%)经历了向精神分裂症的转化。20 年后,总体转化率为 33.1%(95%置信区间,29.3%-37.3%),而大麻使用障碍者的转化率为 58.2%(95%置信区间,44.8%-72.2%)。在完全调整的模型中,任何物质使用障碍都与向精神分裂症的转化有关(HR,1.34;95%置信区间,1.11-1.63)。当按物质进行分层时,大麻使用障碍(HR,1.30;95%置信区间,1.01-1.68)、苯丙胺使用障碍(HR,1.90;95%置信区间,1.14-3.17)和阿片类物质使用障碍(HR,2.74;95%置信区间,1.38-5.45)与向精神分裂症的转化有关。这些关联不能用同时使用抗精神病药物、精神分裂症谱系障碍前的功能水平或父母精神疾病史来解释。
物质使用障碍,特别是大麻、苯丙胺和阿片类物质,可能与精神分裂症谱系障碍向精神分裂症的转化有关。然而,即使在没有物质使用障碍的情况下,转化率也很高,这表明需要对精神分裂症谱系障碍患者进行普遍的和针对物质的预防。